Back to Results

Controlling and Preventing Asthma Progression and Severity in Kids with Omalizumab

Primary Objective

Studies show that up to 80% of children ages 2 to 3 years old who have allergies and multiple wheezing episodes will eventually develop asthma. What if there were a way to reduce the risk of asthma developing in young children? Researchers across the United States are studying weather Xolair can help prevent lasting, severe asthma and new allergies from developing, or reduce the severity of existing ones, in preschool-age children. If your child is 2 or 3 years old, he or she may be eligible to participate in this clinical study.

Study category: Immune System and Allergy

Is this Study for You?

Let's Get Started!

Description

Randomized, Double blinded, placebo controlled, multiple-center, parallel arm study with 96 week treatment phase and 96 week observation phase

Details
Age

Child

Eligibility

1. Age range: 24 through 47 months of age at the screening visit; participant must be under 4 years of age at the time of the randomization visit 2. 2 to 4 wheezing episodes in the past year documented on physical examination by a health care provider 3. Report of a diagnosis of asthma or allergy by a medical professional, or a positive test for allergy (skin test or serum test) in a first degree relative

Type of Study

Treatment

Scope

National

Location

Childrens Hospital Colorado

Principal Investigator
Andrew Liu,  MD

Andrew Liu, MD

Study ID

Protocol Number: 18-2286

More information available at ClinicalTrials.gov: NCT02570984

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers